Ivantis HYDRUS II Glaucoma Study Met Primary Endpoint In a Randomized Controlled Trial at 2 Years
Related Posts
EdgeQ Closes $75M Series-B Investment and Ramps to Customers’ Demand for Its Award-Winning 5G+AI Base Station-on-a-Chip for 5G Networks
- 02 05 2023
- |
Proxtera announces successful first close, of Series Seed round of funding with Ant Group, CerraCap Ventures, and EDBI
- 30 03 2023
- |
